In a 69-year-old man with a provoked left-leg deep vein thrombosis after a knee injection, who completed three months of apixaban (Eliquis) with clot resolution and is reported to have a hypercoagulable state, should he be placed on lifelong low-dose aspirin 81 mg?

Should This Patient Receive Lifelong Aspirin 81 mg?

No, this patient should NOT receive lifelong aspirin 81 mg after completing 3 months of anticoagulation for a provoked DVT. Instead, if extended anticoagulation is warranted due to the reported hypercoagulable state, reduced-dose apixaban (2.5 mg twice daily) is strongly preferred over aspirin. 1, 2

Understanding the Clinical Context

This patient had a provoked DVT following a knee injection, which represents a transient procedural risk factor. 1 However, the hematologist's assessment of "thick blood" (hypercoagulable state) suggests the presence of enduring risk factors that may increase recurrence risk beyond what would be expected from a purely provoked event.

Key Decision Points

Provoked vs. Unprovoked VTE Classification

• Standard provoked VTE (transient risk factor only): Typically requires only 3 months of anticoagulation with no extended therapy. 1, 3
• Provoked VTE with enduring risk factors: Recent high-quality evidence demonstrates significant benefit from extended anticoagulation. 4
• The 2025 HI-PRO trial showed that patients with provoked VTE plus enduring risk factors had a 90% reduction in recurrent VTE (1.3% vs 10.0%) when treated with reduced-dose apixaban versus placebo for 12 months. 4

Why Not Aspirin?

Aspirin is substantially inferior to anticoagulation for VTE prevention:

• The 2021 CHEST guidelines provide a strong recommendation for reduced-dose DOAC over aspirin for extended-phase anticoagulation. 1
• The 2020 ASH guidelines show that aspirin increases recurrent PE risk 3-fold (RR 3.10) and DVT risk 3-fold (RR 3.15) compared to standard anticoagulation. 2
• Aspirin is only suggested when a patient has already decided to stop anticoagulants and refuses continued anticoagulation. 1

The Appropriate Recommendation

If extended therapy is indicated (based on the hypercoagulable workup):

• First choice: Reduced-dose apixaban 2.5 mg twice daily. 1, 5, 4
• This provides superior VTE prevention with minimal bleeding risk compared to aspirin. 1, 4
• The HI-PRO trial demonstrated only 1 major bleeding event in 300 patients on reduced-dose apixaban over 12 months. 4

If the patient refuses all anticoagulation:

• Only then consider aspirin 81-100 mg daily as a weak alternative. 1
• This represents a compromise position with significantly reduced efficacy. 2

Critical Caveats

Hypercoagulable State Clarification Needed

• The term "thick blood" requires specific definition—what thrombophilia was identified? 3
• Inherited thrombophilias (Factor V Leiden, Prothrombin G20210A mutation, protein C/S deficiency) may warrant extended anticoagulation. 3
• Acquired conditions (obesity, heart failure, chronic inflammatory states) also constitute enduring risk factors. 4, 6
• The decision for extended therapy should be reassessed at least annually. 1

Bleeding Risk Assessment

• If this patient has high bleeding risk, the decision becomes more nuanced, potentially favoring stopping anticoagulation at 3 months. 1, 3
• However, reduced-dose apixaban has demonstrated excellent safety even in extended treatment. 4
• Aspirin does NOT eliminate bleeding risk—it still causes bleeding complications. 2

Practical Algorithm

1. Confirm the hypercoagulable diagnosis with specific testing results from hematology
2. If significant enduring risk factors present: Offer reduced-dose apixaban 2.5 mg twice daily for extended duration 1, 4
3. If patient refuses anticoagulation: Consider aspirin 81 mg daily as inferior alternative 1
4. If purely provoked with no enduring factors: Stop anticoagulation at 3 months, no aspirin needed 1, 3
5. Reassess decision annually and with any significant health status changes 1

Bottom Line

The notion that aspirin is an appropriate "middle ground" for this patient is not supported by current evidence. 1, 2 The choice is between continued reduced-dose anticoagulation (if enduring risk factors warrant it) or stopping all antithrombotic therapy (if the DVT was truly provoked without enduring factors). Aspirin should only enter the discussion if the patient categorically refuses anticoagulation despite being a candidate for it. 1